1. Home
  2. HRMY vs ERO Comparison

HRMY vs ERO Comparison

Compare HRMY & ERO Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.

Logo Harmony Biosciences Holdings Inc.

HRMY

Harmony Biosciences Holdings Inc.

HOLD

Current Price

$41.14

Market Cap

2.5B

Sector

Health Care

ML Signal

HOLD

Logo Ero Copper Corp.

ERO

Ero Copper Corp.

HOLD

Current Price

$37.87

Market Cap

2.8B

Sector

N/A

ML Signal

HOLD

Company Overview

Basic Information
Metric
HRMY
ERO
Founded
2017
2016
Country
United States
Canada
Employees
N/A
N/A
Industry
Biotechnology: Pharmaceutical Preparations
Sector
Health Care
Exchange
Nasdaq
Nasdaq
Market Cap
2.5B
2.8B
IPO Year
2020
2021

Fundamental Metrics

Financial Performance
Metric
HRMY
ERO
Price
$41.14
$37.87
Analyst Decision
Buy
Buy
Analyst Count
9
2
Target Price
★ $44.11
$36.50
AVG Volume (30 Days)
849.5K
★ 1.3M
Earning Date
05-07-2026
05-04-2026
Dividend Yield
N/A
N/A
EPS Growth
★ 7.97
N/A
EPS
★ 1.84
N/A
Revenue
★ $868,453,000.00
N/A
Revenue This Year
$19.75
$51.94
Revenue Next Year
$12.88
$2.43
P/E Ratio
★ $22.37
$22.61
Revenue Growth
★ 21.51
N/A
52 Week Low
$25.52
$18.81
52 Week High
$43.49
$40.83

Technical Indicators

Market Signals
Indicator
HRMY
ERO
Relative Strength Index (RSI) 52.86 59.07
Support Level $40.92 $32.89
Resistance Level $43.38 $40.00
Average True Range (ATR) 1.21 1.52
MACD -0.27 0.12
Stochastic Oscillator 40.51 81.09

Price Performance

Historical Comparison
HRMY
ERO

About HRMY Harmony Biosciences Holdings Inc.

Harmony Biosciences Holdings Inc is a commercial-stage pharmaceutical company focused on developing and commercializing therapies for patients living with rare neurological diseases who have unmet medical needs. The company has one reportable segment: rare neurological diseases. Its product WAKIX (pitolisant) is a molecule with a novel mechanism of action specifically designed to increase histamine signaling in the brain by binding to H3 receptors and is used for the treatment of cataplexy in adult patients with narcolepsy. The other drug candidates in its pipeline are Pitolisant, HBS-102 (MCHR1 antagonist), BP1.15205 (orexin-2 receptor agonist), ZYN002 (cannabidiol gel), EPX-100 (clemizole hydrochloride), and EPX-200 (lorcaserin), among others.

About ERO Ero Copper Corp.

Ero Copper Corp is a high-margin, high-growth copper producer with operations in Brazil. Its primary asset is its 99.6% ownership interest in Mineracao Caraiba S.A., held indirectly through its wholly-owned subsidiary. The company also owns a 97.6% ownership interest in NX Gold S.A. indirectly through its wholly-owned subsidiary. Its reporting segments include its three operating mines in Brazil, the Caraiba Operations, the Tucuma Operation, and the Xavantina Operations, and its corporate head office in Canada.

Share on Social Networks: